CD8A and triple-negative breast carcinoma: Moreover, Zhou et al. reported that EVO combined with anti-PD-1 therapy significantly increased the proportions of intratumoral CD4+ and CD8+ T cells, as well as central memory T cells (TCMs) in the spleen, thereby demonstrating potent immunotherapeutic efficacy in triple-negative breast cancer 53.